171 related articles for article (PubMed ID: 24671465)
1. Bone marrow microenvironment confers imatinib resistance to chronic myelogenous leukemia and oroxylin A reverses the resistance by suppressing Stat3 pathway.
Li X; Miao H; Zhang Y; Li W; Li Z; Zhou Y; Zhao L; Guo Q
Arch Toxicol; 2015 Jan; 89(1):121-36. PubMed ID: 24671465
[TBL] [Abstract][Full Text] [Related]
2. Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance.
Bewry NN; Nair RR; Emmons MF; Boulware D; Pinilla-Ibarz J; Hazlehurst LA
Mol Cancer Ther; 2008 Oct; 7(10):3169-75. PubMed ID: 18852120
[TBL] [Abstract][Full Text] [Related]
3. Sonic hedgehog signaling regulates Bcr-Abl expression in human chronic myeloid leukemia cells.
Liao HF; Su YC; Zheng ZY; Jhih Cai C; Hou MH; Chao KS; Chen YJ
Biomed Pharmacother; 2012 Jul; 66(5):378-83. PubMed ID: 22397755
[TBL] [Abstract][Full Text] [Related]
4. Synergistic killing effect of imatinib and simvastatin on imatinib-resistant chronic myelogenous leukemia cells.
Oh B; Kim TY; Min HJ; Kim M; Kang MS; Huh JY; Kim Y; Lee DS
Anticancer Drugs; 2013 Jan; 24(1):20-31. PubMed ID: 23075630
[TBL] [Abstract][Full Text] [Related]
5. [Growth inhibition and differentiation of imatinib-resistant chronic myeloid leukemia cell induced by cell differentiation agent in vitro].
Wang XD; Qiu L; Lu RZ; Chen LJ; Zhan ZM; Han BH; Zhang BL; Ma J
Zhonghua Yi Xue Za Zhi; 2007 Dec; 87(48):3399-405. PubMed ID: 18476538
[TBL] [Abstract][Full Text] [Related]
6. A new nonpeptidic inhibitor of 14-3-3 induces apoptotic cell death in chronic myeloid leukemia sensitive or resistant to imatinib.
Mancini M; Corradi V; Petta S; Barbieri E; Manetti F; Botta M; Santucci MA
J Pharmacol Exp Ther; 2011 Mar; 336(3):596-604. PubMed ID: 21041536
[TBL] [Abstract][Full Text] [Related]
7. Loss of P-glycoprotein expression in hematopoietic stem cells does not improve responses to imatinib in a murine model of chronic myelogenous leukemia.
Zong Y; Zhou S; Sorrentino BP
Leukemia; 2005 Sep; 19(9):1590-6. PubMed ID: 16001089
[TBL] [Abstract][Full Text] [Related]
8. Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell-cycle arrest, caspase-3 activation, and downregulation of Cox-2 expression and are synergistic with hydroxyurea or imatinib.
Zhang GS; Liu DS; Dai CW; Li RJ
Am J Hematol; 2006 Apr; 81(4):242-55. PubMed ID: 16550520
[TBL] [Abstract][Full Text] [Related]
9. Characteristics of dasatinib- and imatinib-resistant chronic myelogenous leukemia cells.
Okabe S; Tauchi T; Ohyashiki K
Clin Cancer Res; 2008 Oct; 14(19):6181-6. PubMed ID: 18829496
[TBL] [Abstract][Full Text] [Related]
10. Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development.
Burchert A; Wang Y; Cai D; von Bubnoff N; Paschka P; Müller-Brüsselbach S; Ottmann OG; Duyster J; Hochhaus A; Neubauer A
Leukemia; 2005 Oct; 19(10):1774-82. PubMed ID: 16136169
[TBL] [Abstract][Full Text] [Related]
11. Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cells.
Gottschalk S; Anderson N; Hainz C; Eckhardt SG; Serkova NJ
Clin Cancer Res; 2004 Oct; 10(19):6661-8. PubMed ID: 15475456
[TBL] [Abstract][Full Text] [Related]
12. Adaphostin has significant and selective activity against chronic and acute myeloid leukemia cells.
Orsolic N; Golemovic M; Quintás-Cardama A; Scappini B; Manshouri T; Chandra J; Basic I; Giles F; Kantarjian H; Verstovsek S
Cancer Sci; 2006 Sep; 97(9):952-60. PubMed ID: 16822295
[TBL] [Abstract][Full Text] [Related]
13. Establishment of a new Glivec-resistant chronic myeloid leukemia cell line, SNUCML-02, using an in vivo model.
Park J; Kim KI; Koh Y; Won NH; Oh JM; Lee DS; Kim BK; Ahn KS; Yoon SS
Exp Hematol; 2010 Sep; 38(9):773-81. PubMed ID: 20438801
[TBL] [Abstract][Full Text] [Related]
14. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
[TBL] [Abstract][Full Text] [Related]
15. Label-free MSE proteomic analysis of chronic myeloid leukemia bone marrow plasma: disclosing new insights from therapy resistance.
Pizzatti L; Panis C; Lemos G; Rocha M; Cecchini R; Souza GH; Abdelhay E
Proteomics; 2012 Aug; 12(17):2618-31. PubMed ID: 22761178
[TBL] [Abstract][Full Text] [Related]
16. Persistent activation of the Fyn/ERK kinase signaling axis mediates imatinib resistance in chronic myelogenous leukemia cells through upregulation of intracellular SPARC.
Fenouille N; Puissant A; Dufies M; Robert G; Jacquel A; Ohanna M; Deckert M; Pasquet JM; Mahon FX; Cassuto JP; Raynaud S; Tartare-Deckert S; Auberger P
Cancer Res; 2010 Dec; 70(23):9659-70. PubMed ID: 21098700
[TBL] [Abstract][Full Text] [Related]
17. Contribution of BCR-ABL-independent activation of ERK1/2 to acquired imatinib resistance in K562 chronic myeloid leukemia cells.
Nambu T; Araki N; Nakagawa A; Kuniyasu A; Kawaguchi T; Hamada A; Saito H
Cancer Sci; 2010 Jan; 101(1):137-42. PubMed ID: 19843070
[TBL] [Abstract][Full Text] [Related]
18. Reversal of the resistance to STI571 in human chronic myelogenous leukemia K562 cells.
Mukai M; Che XF; Furukawa T; Sumizawa T; Aoki S; Ren XQ; Haraguchi M; Sugimoto Y; Kobayashi M; Takamatsu H; Akiyama S
Cancer Sci; 2003 Jun; 94(6):557-63. PubMed ID: 12824882
[TBL] [Abstract][Full Text] [Related]
19. [Effects of HO-1 gene expression on proliferation of imatinib resistant CML cells].
Wang JS; Chai BS; Fang Q; He YY; Chen C; Yang C
Zhonghua Xue Ye Xue Za Zhi; 2011 Jun; 32(6):388-91. PubMed ID: 21781496
[TBL] [Abstract][Full Text] [Related]
20. Enhanced CML stem cell elimination in vitro by bryostatin priming with imatinib mesylate.
Jørgensen HG; Allan EK; Mountford JC; Richmond L; Harrison S; Elliott MA; Holyoake TL
Exp Hematol; 2005 Oct; 33(10):1140-6. PubMed ID: 16219536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
